In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC’s Salvos Against Biopharma To Reverberate Through 2024

Executive Summary

The Federal Trade Commission broke new ground last year in its opposition to M&A transactions and challenge of Orange Book patent listings. The biopharma community is waiting to see if deals will face similar hurdles in 2024 and whether there will be legal battles if manufacturers of drug-device combination products decline to delist their patents. Researchers advocate that the FTC extend its inquiry to device patents on GLP-1 receptor agonists, including Wegovy and Ozempic.

You may also be interested in...

FTC, HHS Probe GPO Contracting Practices As Source Of Generic Drug Shortages

Contracting practices and lack of competition among large healthcare group purchasing organizations and drug wholesalers – and their impact on the generic pharmaceutical market – are among topics in request for public comments by the agency.

As Bernie Focuses On Older Drug-Device Combos, Can Innovators Catch Their Breath?

Product hopping, patent manipulation, patient assistance programs and pay-for-delay are all points of inquiry in Sen. Bernie Sanders and fellow HELP Democrats latest drug pricing investigation, which targets pricey inhalers that have gone decades without generic competition.

US FTC Ruffles Pharma’s Feathers Again

Dust has barely settled around the uncertainty stirred up by the Federal Trade Commission’s view of the Amgen/Horizon merger and now the US regulator is taking another surprising action.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts